Targeted insight is essential for making informed decisions in the drug design process. Which parameters affect the biological activity of my compound series? perhaps assessed relatively easily for a small number of compounds, establishing SARs across a compound series spanning multiple scaffolds and chemotypes becomes far more challenging. This is exactly where the latest release of our drug design dashboard comes in: SeeSAR 15 ‘Apollo’.
In this webinar, we will showcase the new Activity Spotter mode, which identifies the 3D features that drive or prevent biological activity across a series of aligned molecules. We will also explore additional new developments in SeeSAR 15, including loop modeling, quality-of-life improvements to hydrogen-bond interaction visualization, multiple-template docking, MPO scoring, and resource-efficient molecule filtering.
We look forward to presenting and discussing the 50th release of SeeSAR with you.
You can find the full changelog following this link.
